INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 424m ago
HOUSE PTR24m ago
SEC 13F24m ago
ROBINHOOD CHAIN24m ago
SEC FORM 4/Grant or awardVerified data

Winter Charles M. reported JANX

Chief Technical Officer · Janux Therapeutics, Inc. · Janux Therapeutics, Inc. — Stock option (right to buy)

Side
A
Value
—
Shares
100.1K
Price
—
Executed
Jan 2, 2026
Disclosed
Jan 2, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jan 2 executedJan 2, 2026 disclosed

JANX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · JANX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    28
    DN
    Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$57K
    4,059 sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    DM
    Dobek MariaVice President, Accounting
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$29K
    2,038 sh
    		May 11, 2026May 13, 2026
    traded May 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GW
    Go WilliamChief Medical Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    44.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GW
    Go WilliamChief Medical Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    154.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    40
    MZ
    McIver ZachariahChief Medical Officer
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$37K
    2,714 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    21
    MZ
    McIver ZachariahChief Medical Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    29.0K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    21
    DM
    Dobek MariaVice President, Accounting
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    18.9K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DM
    Dobek MariaVice President, Accounting
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    42.6K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    17
    DT
    DiRaimondo ThomasChief Scientific Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    31.4K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DT
    DiRaimondo ThomasChief Scientific Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    109.9K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    17
    WM
    Winter Charles M.Chief Technical Officer
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    28.6K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    17
    CA
    Campbell David AlanDirector, President and CEO
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    96.6K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CA
    Campbell David AlanDirector, President and CEO
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    338.1K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DN
    Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    126.0K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    40
    DM
    Dobek MariaVice President, Accounting
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$20K
    1,462 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    36
    WM
    Winter Charles M.Chief Technical Officer
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$33K
    2,401 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    36
    DT
    DiRaimondo ThomasChief Scientific Officer
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$34K
    2,505 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    39
    CA
    Campbell David AlanDirector, President and CEO
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$111K
    8,072 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    21
    DN
    Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
    JANXJanux Therapeutics, Inc.
    Grant or award
    		A—
    36.0K sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    32
    MH
    Meyer Andrew HollmanChief Business Officer
    JANXJanux Therapeutics, Inc.
    Open-market sale
    		SELL$26K
    1,879 sh
    		Jan 2, 2026Jan 2, 2026
    traded Jan 2, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001960264-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 2, 2026
    Published
    Jan 2, 2026
    Ingested by INSIDER
    Nov 5, 04:24 UTC
    Last re-read
    Nov 5, 04:24 UTC

    Extracted facts

    Filer
    Winter Charles M.
    Role
    Chief Technical Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Janux Therapeutics, Inc. — Stock option (right to buy)
    Ticker
    JANX
    Shares
    100.1K
    Price per share
    $0
    Execution date (reported)
    Jan 2, 2026
    Owned after transaction
    100.1K shares
    Days from execution to publication
    0

    What this establishes

    Winter Charles M. filed this Form 4 reporting a grant or award of JANX on Jan 2, 2026. It became public on Jan 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Technical Officer
    Winter Charles M.cik:0001960264
    Issuer
    Janux Therapeutics, Inc.cik:0001817713

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.